This new version of Myrian® brings many clinical innovations and a new application.

Achieving a positive Net Income within this first 2019 semester validates the strategic choices set by the new governance in 2018, generating profits for the first half of 2019 financial year.

Myrian® XP-Mammo, can now be commercialized on the European market.

Myrian® XP Prostate, the new reference tool for worldwide prostate experts.

Elonav, a brand-new application dedicated to specifical needs of neurosurgeons.